The Future of oHCM Treatment
Andrew Wang, MD; James Januzzi, MD; Michelle M. Kittleson, MD, PhD; and Milind Desai, MD, MBA, share a look into the future of oHCM treatment.
Unanswered Questions About CMIs in oHCM
Michelle M. Kittleson, MD, PhD, comments on remaining unanswered questions regarding CMIs in treatment of oHCM, highlighting disease modification.
Implementing Novel Agents in the Treatment of oHCM
Expert cardiologists share approaches to implementing mavacamten and aficamten in the clinical treatment of oHCM.
Clinical Trials of Aficamten in oHCM
Andrew Wang, MD, and Anjali Owens, MD, review the clinical trials of aficamten, a CMI used for treating patients with oHCM.
Clinical Trials of Mavacamten in oHCM
Milind Desai, MD, MBA, and Michelle M. Kittleson, MD, PhD, review the clinical trial data of mavacamten, the first FDA-approved cardiac myosin inhibitor for the treatment of oHCM.
Use of Cardiac Myosin Inhibitors (CMI) in oHCM
Andrew Wang, MD, discusses the use of cardiac myosin inhibitors (CMIs) as a new, less invasive option for treating oHCM.
Advances in oHCM Therapy
Milind Desai, MD, MBA, comments on the broadening knowledge in the oHCM space, leading to the development of new therapies.
Septal Reduction Therapies in oHCM
Expert cardiologists share approaches to the challenges that come with septal reduction therapy, as well as access to oHCM treatment.
Guideline-Directed Therapy in oHCM
Andrew Wang, MD, comments on the treatment algorithm for symptomatic oHCM, highlighting treatment guidelines, and James Januzzi, MD, reviews treatment selection for oHCM through the lens of the patient’s quality of life.
Goals of Treatment in Symptomatic oHCM
Expert cardiologists discuss treating patients with symptomatic vs asymptomatic oHCM.
Approaches to Imaging in oHCM
Milind Desai, MD, MBA, leads a discussion on the importance of accurate imaging in oHCM and aortic stenosis, highlighting the echocardiogram and doppler tests.
Risk Stratification in oHCM
Milind Desai, MD, MBA, comments on risk stratification for sudden cardiac death (SCD) in oHCM.
Impact of Diagnosis of oHCM
Cardiology experts discuss the importance of an accurate and prompt diagnosis of oHCM, as well as effectively educating the patient about the condition.
Signs and Symptoms of oHCM
Michelle M. Kittleson, MD, PhD, and James Januzzi, MD, review signs that point to oHCM, highlighting family history and details on the diagnostic evaluation.
The Pathophysiology of Obstructive Hypertrophic Cardiomyopathy (oHCM)
Andrew Wang, MD, outlines the epidemiology of obstructive hypertrophic cardiomyopathy (oHCM), and Milind Desai, MD, MBA, reviews the etiology of the condition.
2 Clarke Drive Cranbury, NJ 08512